Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease ; volume:13 ; number:1 ; day:22 ; month:9 ; year:2023 ; pages:1-15 ; date:12.2023
Scientific reports ; 13, Heft 1 (22.9.2023), 1-15, 12.2023
- Urheber
-
Arav, Yehuda
Zohar, Assaf
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-42878-5
- URN
-
urn:nbn:de:101:1-2024020512145987920935
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Arav, Yehuda
- Zohar, Assaf
- SpringerLink (Online service)
Ähnliche Objekte (12)
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
Charakteristika der Unified Parkinson’s Disease Rating Scale im Rahmen der Levodopa-Response
Levodopa-Responsive Primary Slow Orthostatic Tremor: A Premotor Sign of Parkinson’s Disease?
Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
Charakteristika der Unified Parkinson’s Disease Rating Scale im Rahmen der Levodopa-Response
Levodopa-Responsive Primary Slow Orthostatic Tremor: A Premotor Sign of Parkinson’s Disease?
Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
Charakteristika der Unified Parkinson’s Disease Rating Scale im Rahmen der Levodopa-Response
Levodopa-Responsive Primary Slow Orthostatic Tremor: A Premotor Sign of Parkinson’s Disease?
Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age